<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979953</url>
  </required_header>
  <id_info>
    <org_study_id>44CL240</org_study_id>
    <nct_id>NCT00979953</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of ADL5859 and ADL5747 in Subjects With Moderate to Severe Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of ADL5859 versus placebo and ADL5747
      versus placebo in relieving pain in participants with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Average Pain Score (NPRS) for Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>The mean of the daily average scores were calculated from the NPRS pain assessment for the previous 24 hours obtained once a day for at least 4 days from Day -6 through Day 1 (Baseline assessment) and everyday from Day 2 through Day 15 (Treatment Phase assessment). The NPRS is an 11-point scale (0 to 10) with 0 indicating no pain and 10 indicating the worst possible pain.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>ADL5859</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADL5747</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone CR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4
One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four placebo capsules administered orally BID for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADL5859</intervention_name>
    <arm_group_label>ADL5859</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADL5747</intervention_name>
    <arm_group_label>ADL5747</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone CR</intervention_name>
    <arm_group_label>Oxycodone CR</arm_group_label>
    <other_name>OxyContin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>ADL5859</arm_group_label>
    <arm_group_label>ADL5747</arm_group_label>
    <arm_group_label>Oxycodone CR</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  a man or woman between 18 and 75 years of age, inclusive

          -  for women of childbearing potential, be using an insertable, injectable, transdermal,
             or combination oral contraceptive deemed highly effective by the United States Food
             and Drug Administration from the first dose of study medication through the end of the
             study and have negative findings on pregnancy tests performed at screening and
             randomization (women who are surgically sterile [for example, hysterectomy, tubal
             ligation] or postmenopausal [if ≥55 years old, no menses for at least 2 years; if &lt;55
             years old, follicle-stimulating hormone concentrations within the postmenopausal range
             of &gt;40 milli-international units per milliliter (mIU/mL) and 17 β-estradiol levels of
             &lt;37 picograms per milliliter (pg/mL)] are also eligible to participate)

          -  for male participants, be surgically sterile or agree to use an appropriate method of
             contraception (that is, use a barrier method in conjunction with spermicide or have a
             sexual partner who is surgically sterile, postmenopausal, or using an insertable,
             injectable, transdermal, or combination oral contraceptive deemed highly effective by
             the United States Food and Drug Administration) from the first dose of study
             medication through the end of the study

          -  have a body weight between 45 and 150 kilograms (kg), inclusive

          -  have had pain in the index knee for at least the past 6 months

          -  meet the following criteria for osteoarthritis of the knee established by the American
             College of Rheumatology (radiographs must have been taken within the last year; if
             none is available, a radiograph must be taken and the diagnostic criteria must be
             confirmed before the participant is enrolled in the study): have index knee pain plus
             at least 1 moderate or definite osteophyte on radiographs. Must also have at least 1
             of the following: be more than 50 years old, have morning stiffness for less than 30
             minutes, or have crepitus on active motion

          -  have an average weekly pain score of at least 4.00 on the numeric pain rating scale
             (NPRS) for the index knee during the baseline week before randomization (to be
             eligible for randomization, participants must report their NPRS score via the
             interactive voice-response system (IVRS) for at least 4 of the 7 days immediately
             before randomization, with the first score being recorded on Day -6)

          -  if receiving nonselective or selective cyclooxygenase (COX) inhibitors, have a stable
             daily dose regimen for at least 4 weeks before screening; if receiving nonselective or
             selective COX inhibitors on an as needed basis, have discontinued use by Day -14; if
             receiving angiotensin-converting enzyme (ACE) inhibitors, have a stable dose regimen
             for at least 4 weeks before screening

        Key Exclusion Criteria:

          -  have undergone arthroscopy on the index knee within 6 months before study entry

          -  have other severe pain that, in the opinion of the investigator, may impair the
             assessment of the pain due to osteoarthritis

          -  have a history of hypersensitivity or intolerance to opioids (including tramadol and
             tapentadol)

          -  have, as determined by the investigator or the sponsor's medical monitor, a history or
             clinical manifestations of significant renal, hepatic, hematologic, cardiovascular,
             metabolic, gastrointestinal, neurologic, psychiatric, or another condition that would
             preclude participation in the study or affect the outcome of the study

          -  have taken oral or intramuscular corticosteroids within 30 days before study entry
             (inhaled or topical corticosteroids are permitted)

          -  have received intra-articular injections of corticosteroids into the index joint
             within 12 weeks before screening

          -  have received intra-articular injections of hyaluronic acid into the index joint
             within 24 weeks before screening

          -  currently taking medications other than nonsteroidal anti-inflammatory drugs
             prescribed for chronic pain (such as duloxetine or pregabalin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Berger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cubist Pharmaceuticals LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance CRU, Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Knee and Shoulder Clinic, PC</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Rheumatoloty Center for Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cresent Medical Research</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hanover Medical Research</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PSB Research</name>
      <address>
        <city>Mt Gilead</city>
        <state>Ohio</state>
        <zip>43338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone Joint &amp; Spine Surgeons, Inc</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radient Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <results_first_submitted>April 21, 2015</results_first_submitted>
  <results_first_submitted_qc>April 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2015</results_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>delta opioid receptor agonist</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ADL5859</title>
          <description>One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days</description>
        </group>
        <group group_id="P2">
          <title>ADL5747</title>
          <description>One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days</description>
        </group>
        <group group_id="P3">
          <title>Oxycodone CR</title>
          <description>One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4 One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Four placebo capsules administered orally BID for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>ADL5859</title>
          <description>One 50-mg ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally BID for 14 days</description>
        </group>
        <group group_id="B2">
          <title>ADL5747</title>
          <description>One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Oxycodone CR</title>
          <description>One 10-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 1 through 4
One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Four placebo capsules administered orally BID for 14 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="104"/>
            <count group_id="B4" value="104"/>
            <count group_id="B5" value="408"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="8.15"/>
                    <measurement group_id="B2" value="57.3" spread="8.74"/>
                    <measurement group_id="B3" value="57.8" spread="8.39"/>
                    <measurement group_id="B4" value="56.5" spread="8.11"/>
                    <measurement group_id="B5" value="57.0" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Average Pain Score (NPRS) for Week 2</title>
        <description>The mean of the daily average scores were calculated from the NPRS pain assessment for the previous 24 hours obtained once a day for at least 4 days from Day -6 through Day 1 (Baseline assessment) and everyday from Day 2 through Day 15 (Treatment Phase assessment). The NPRS is an 11-point scale (0 to 10) with 0 indicating no pain and 10 indicating the worst possible pain.</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>All participants who received at least 1 dose of study medication and had at least evaluable 1 NPRS postdose measurement. Last-observation-carried-forward (LOCF) was used to impute missing postbaseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Four placebo capsules administered orally BID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone CR</title>
            <description>One 10-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 1 through 4
One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID for Days 5 through 14</description>
          </group>
          <group group_id="O3">
            <title>ADL5747</title>
            <description>One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>ADL5859</title>
            <description>One 50-mg ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally BID for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Average Pain Score (NPRS) for Week 2</title>
          <description>The mean of the daily average scores were calculated from the NPRS pain assessment for the previous 24 hours obtained once a day for at least 4 days from Day -6 through Day 1 (Baseline assessment) and everyday from Day 2 through Day 15 (Treatment Phase assessment). The NPRS is an 11-point scale (0 to 10) with 0 indicating no pain and 10 indicating the worst possible pain.</description>
          <population>All participants who received at least 1 dose of study medication and had at least evaluable 1 NPRS postdose measurement. Last-observation-carried-forward (LOCF) was used to impute missing postbaseline values.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="2.088"/>
                    <measurement group_id="O2" value="-2.24" spread="2.162"/>
                    <measurement group_id="O3" value="-1.57" spread="1.656"/>
                    <measurement group_id="O4" value="-1.77" spread="1.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ADL5859</title>
          <description>One 50-mg ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally BID for 14 days</description>
        </group>
        <group group_id="E2">
          <title>ADL5747</title>
          <description>One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days</description>
        </group>
        <group group_id="E3">
          <title>Oxycodone CR</title>
          <description>One 10-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 1 through 4
One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Four placebo capsules administered orally BID for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease (COPD)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP of Clinical Research</name_or_title>
      <organization>Cubist Pharmaceuticals</organization>
      <phone>(781) 860-8660</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

